A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and
determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma,
adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm
and other advanced solid tumors.